Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1979 Mar;65(3):489–494. doi: 10.1111/j.1476-5381.1979.tb07856.x

The effect of pargyline and desmethylimipramine on monoamine concentrations and amphetamine-induced glycogenolysis in the mouse brain.

D A Hutchins
PMCID: PMC1668631  PMID: 427324

Abstract

1. Pargyline (100 mg/kg) increased the concentration of cerebral noradrenaline dopamine and 5-hydroxytryptamine in the mouse. Amphetamine (5 mg/kg) reduced the concentration of noradrenaline and increased the concentrations of 5-hydroxytryptamine and dopamine. 2. When amphetamine was administered 4 h after an injection of pargyline, the effect of the sympathomimetic drug on the concentrations of noradrenaline and 5-hydroxytryptamine was not altered. The effect on the dopamine content was reversed, amphetamine causing a decrease instead of an increase. 3. Pargyline increased the concentration of cerebral glycogen, whereas amphetamine caused a decrease. 4. The administration of amphetamine 4 h after pargyline resulted in a decrease in brain glycogen similar to that seen after amphetamine alone. 5. These results suggest that the potentiation of the effect of amphetamine on animal behaviour by pretreatment with an inhibitor of monoamine oxidase is not mediated through a central action on noradrenaline release. 6. Amphetamine-induced glycogenolysis was antagonized by 71% by desmethylimipramine (10 mg/kg). 7. The change in glycogen concentration as a function of time after an injection of amphetamine was not modified when 2 consecutive doses of amphetamine were given with an interval between doses of 30 minutes.

Full text

PDF
489

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANTON A. H., SAYRE D. F. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther. 1962 Dec;138:360–375. [PubMed] [Google Scholar]
  2. BOGDANSKI D. F., PLETSCHER A., BRODIE B. B., UNDENFRIEND S. Identification and assay of serotonin in brain. J Pharmacol Exp Ther. 1956 May;117(1):82–88. [PubMed] [Google Scholar]
  3. BRITTAIN R. T., JACK D., SPENCER P. S. MECHANISM OF ACTION OF MONOAMINE OXIDASE INHIBITORS IN ENHANCING AMPHETAMINE TOXICITY. J Pharm Pharmacol. 1964 Aug;16:565–567. doi: 10.1111/j.2042-7158.1964.tb07515.x. [DOI] [PubMed] [Google Scholar]
  4. BRITTAIN R. T., SPENCER P. S. MEASUREMENT OF BODY TEMPERATURE IN CONSCIOUS SMALL LABORATORY ANIMALS BY MEANS OF AN OESOPHAGEAL THERMOCOUPLE. J Pharm Pharmacol. 1964 Jul;16:497–499. doi: 10.1111/j.2042-7158.1964.tb07501.x. [DOI] [PubMed] [Google Scholar]
  5. BROWNLEE G., WILLIAMS G. W. Potentiation of amphetamine and pethidine by monoamineoxidase inhibitors. Lancet. 1963 Mar 23;1(7282):669–669. doi: 10.1016/s0140-6736(63)91307-2. [DOI] [PubMed] [Google Scholar]
  6. CARLSSON A., DAHLSTROEM A., FUXE K., LINDQVIST M. HISTOCHEMICAL AND BIOCHEMICAL DETECTION OF MONOAMINE RELEASE FROM BRAIN NEURONS. Life Sci. 1965 Apr;4:809–816. doi: 10.1016/0024-3205(65)90313-9. [DOI] [PubMed] [Google Scholar]
  7. CARLSSON A., WALDECK B. A fluorimetric method for the determination of dopamine (3-hydroxytyramine). Acta Physiol Scand. 1958 Dec 15;44(3-4):293–298. doi: 10.1111/j.1748-1716.1958.tb01628.x. [DOI] [PubMed] [Google Scholar]
  8. CARLTON P. L. Potentiation of the behavioral effects of amphetamine by imipramine. Psychopharmacologia. 1961;2:364–376. doi: 10.1007/BF00404124. [DOI] [PubMed] [Google Scholar]
  9. Carlsson A., Fuxe K., Hamberger B., Lindqvist M. Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol Scand. 1966 Jul-Aug;67(3):481–497. doi: 10.1111/j.1748-1716.1966.tb03334.x. [DOI] [PubMed] [Google Scholar]
  10. Consolo S., Dolfini E., Garattini S., Valzelli L. Desipramine and amphetamine metabolism. J Pharm Pharmacol. 1967 Apr;19(4):253–256. doi: 10.1111/j.2042-7158.1967.tb08080.x. [DOI] [PubMed] [Google Scholar]
  11. DINGELL J. V., SULSER F., GILLETTE J. R. SPECIES DIFFERENCES IN THE METABOLISM OF IMIPRAMINE AND DESMETHYLIMIPRAMINE (DMI). J Pharmacol Exp Ther. 1964 Jan;143:14–22. [PubMed] [Google Scholar]
  12. Dolfini E., Tansella M., Valzelli L., Garattini S. Further studies on the interaction between desipramine and amphetamine. Eur J Pharmacol. 1969 Jan;5(2):185–190. doi: 10.1016/0014-2999(69)90028-4. [DOI] [PubMed] [Google Scholar]
  13. GLOWINSKI J., AXELROD J. INHIBITION OF UPTAKE OF TRITIATED-NORADRENALINE IN THE INTACT RAT BRAIN BY IMIPRAMINE AND STRUCTURALLY RELATED COMPOUNDS. Nature. 1964 Dec 26;204:1318–1319. doi: 10.1038/2041318a0. [DOI] [PubMed] [Google Scholar]
  14. Hutchins D. A., Rogers K. J. Effect of depletion of cerebral monoamines on the concentration of glycogen and on amphetamine-induced glycogenolysis in the brain. Br J Pharmacol. 1973 May;48(1):19–29. doi: 10.1111/j.1476-5381.1973.tb08218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hutchins D. A., Rogers K. J. Effect of receptor blocking drugs on the depletion of brain glycogen by amphetamine. Br J Pharmacol. 1971 Nov;43(3):504–513. doi: 10.1111/j.1476-5381.1971.tb07181.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hutchins D. A., Rogers K. J. Physiological and drug-induced changes in the glycogen content of mouse brain. Br J Pharmacol. 1970 May;39(1):9–25. doi: 10.1111/j.1476-5381.1970.tb09551.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. LEBARON F. N. The resynthesis of glycogen by guinea pig cerebral-cortex slices. Biochem J. 1955 Sep;61(1):80–85. doi: 10.1042/bj0610080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lewander T. Influence of various psychoactive drugs on the in vivo metabolism of d-amphetamine in the rat. Eur J Pharmacol. 1969 Apr;6(1):38–44. doi: 10.1016/0014-2999(69)90062-4. [DOI] [PubMed] [Google Scholar]
  19. Rogers K. J., Hutchins D. A. Studies on the relation of chemical structure to glycogenolytic activity in the brain. Eur J Pharmacol. 1972 Oct;20(1):97–103. doi: 10.1016/0014-2999(72)90221-x. [DOI] [PubMed] [Google Scholar]
  20. SHORE P. A., OLIN J. S. Identification and chemical assay of norepinephrine in brain and other tissues. J Pharmacol Exp Ther. 1958 Mar;122(3):295–300. [PubMed] [Google Scholar]
  21. STEIN L. SELF-STIMULATION OF THE BRAIN AND THE CENTRAL STIMULANT ACTION OF AMPHETAMINE. Fed Proc. 1964 Jul-Aug;23:836–850. [PubMed] [Google Scholar]
  22. Sjöqvist F. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med. 1965 Nov;58(11 Pt 2):967–978. doi: 10.1177/003591576505811P206. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES